Drug Database
Back to search

Belgium· BE-AMP-SAM596400-00

Ozempic 2 mg

A semaglutide product containing semaglutide, registered in Belgium by Novo Nordisk. The same ATC class is registered in 14 of our 19 countries.

ATC A10BJ06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOzempic 2 mgATCA10BJ06REGISTER NO.BE-AMP-SAM596400-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about semaglutideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Semaglutide is registered in 14 of 19 countries.

Countries holding a registration under ATC A10BJ06 (semaglutide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search semaglutide products by name

Semaglutide · ATC A10BJ06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of semaglutide costs, country by country.

Normalised to the WHO defined daily dose (10.5 mg), the median price runs from $11.85 in Italy to $430.99 in Switzerland — a ×36 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Semaglutide · price per daily dose (10.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$430.99
  • IT Italy$11.85
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Semaglutide
Manufacturer
Novo Nordisk
Country
Belgium (BE)
ATC code
A10BJ06
ATC class
Semaglutide
Defined daily dose
10.5 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    5809835

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

301 interactions on record for semaglutide.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check semaglutide against other medicinesHow interaction checks work

Semaglutide · interactions on record

301 records

  • 3 severe
  • 258 moderate
  • 40 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Semaglutide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All semaglutide products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Kayshild, Ozempic
  • Norway · Kayshild, Ozempic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c7687bbf-a810-4eef-9f79-e57cd72b07da
GET /v1/drugs/c7687bbf-a810-4eef-9f79-e57cd72b07da?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled pen",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ozempic 2 mg",
  "name_fr": "Ozempic 2 mg",
  "name_nl": "Ozempic 2 mg",
  "amp_code": "SAM596400-00",
  "strengths": [
    "1.3400"
  ],
  "pack_count": 2,
  "substances": [
    "Semaglutide",
    "Disodium Hydrogen Phosphate Dihydrate",
    "Propylene Glycol",
    "Sodium Hydroxide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Semaglutide",
  "authorisation_numbers": [
    "EU/1/17/1251/010",
    "EU/1/17/1251/011"
  ]
}
API referenceMCP serverPlans

See everything about semaglutide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console